Hantavirus vaccine in 2026?
Yes
2%
No
99%
24h change
-1.7 pts
- Volume
- $154K
- 24h volume
- $10.7K
- Liquidity
- $63.3K
- Updated
- Nov 15, 2026 · 12:50 UTC
Probability over time
Market probability
PolyForecast AI
Price history is still being collected for this range.
AI edge over time
Why the AI forecasts this probability
The AI reasoning appears here once a forecast is generated for this market.
Latest relevant updates
No relevant updates found.
About this market
This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
Market data from Polymarket. PolyForecast is not affiliated with Polymarket.